Departments of Pathology.
Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo.
Am J Surg Pathol. 2018 Nov;42(11):1466-1471. doi: 10.1097/PAS.0000000000000969.
GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.
GNA13 是一种 G 蛋白，参与调节肿瘤的增殖能力、浸润、转移和迁移。GNA13 的基因组改变在滤泡性淋巴瘤（FL）中经常观察到。在这项研究中，我们通过使用组织微阵列对 167 例 FL 进行了 GNA13 的免疫染色，以评估其临床意义。有 26 例 GNA13 阳性病例（15.6%）和 141 例 GNA13 阴性病例（84.4%）。与 GNA13 阴性病例相比，GNA13 阳性病例疾病早期进展的发生率更高，在 2 年内被认为疾病进展（P=0.03）。其他临床病理因素如组织学分级、BCL2-IGH 易位、免疫组化表型和滤泡性淋巴瘤国际预后指数均无显著差异。此外，GNA13 阳性病例的总生存和无进展生存均较 GNA13 阴性病例差（P=0.009 和 0.005）。多因素分析发现，GNA13 阳性是总生存和无进展生存的不良预后因素。因此，GNA13 蛋白表达是独立的预后因素，并可能影响 FL 的疾病进展。
